Happify Health and Almirall Partner Together to Launch Claro
Claro, a digital platform built to improve mental health for those with psoriasis who are living in Spain, the United Kingdom, and Italy.
Friday, August 12, 2022
Psoriasis News
THE LATEST FROM IPC, INDUSTRY AND OTHERS
Results
Lilly Announces a New, Citrate-Free Formulation of Taltz® (ixekizumab)
Eli Lilly announced a new formula for Taltz® that contains the same active ingredient as the original formulation, but patients experience significantly less pain at the injection site.
Wednesday, August 10, 2022
Arcutis Announces FDA Approval for ZORYVE (Roflumilast) Cream 0.3% for Plaque Psoriasis in Individuals Age 12 and Older
ZORYVE is the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved to treat plaque psoriasis. The product is expected to be available mid-August.
Tuesday, August 9, 2022
Arcutis Biotherapeutics, Inc. Announced Findings From the Skin Insights: Uncovering Psoriasis Survey
Arcutis Biotherapeutics, Inc. shared their finding from the Skin Insights: Uncovering Psoriasis Survey.
Thursday, June 2, 2022
Dermavant Announces FDA Approval for VTAMA® (Tapinarof) Cream
Dermavant announced the FDA approval for VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults. This is the first topical novel chemical entity launched for psoriasis in the U.S. in 25 years.
Thursday, May 26, 2022
Bristol Myers Squibb (BMS) Announces New Two-Year Deucravacitinib Data
Bristol Myers Squibb (BMS) announced new two-year data that reinforces the durable efficacy and consistent safety profile of Deucravacitinib when used to treat moderate to severe plaque psoriasis.
Monday, May 16, 2022
Amgen Announces New Otezla (Apremilast) Data
Amgen presents new data on the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis.
Tuesday, April 5, 2022
Janssen Initiates First-of-its-kind Clinical Study to Bridge Critical Gaps in Care for People of Color With Moderate to Severe Plaque Psoriasis
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of VISIBLE. VISIBLE is a first-of-its-kind, large-scale prospective clinical study dedicated to generating key disease insights among Black, Hispanic, Asian, Indigenous, and other people of color.
Monday, April 4, 2022
Subscribe to the IPC Newsletter
We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.
